Wide Ranks

CTXR

Citius Pharmaceuticals, Inc.

3.60

Top Statistics
Market Cap 27 M Forward PE 28.80 Revenue Growth 0.00 %
Current Ratio 6.75 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -15.43 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 17 M Total Cash Per Share 0.0990 Total Debt 320011
Total Debt To Equity 0.3710 Current Ratio 6.75 Book Value Per Share 0.4740
All Measures
Short Ratio 744.00 % Message Board Id finmb_272471835 Shares Short Prior Month 496878
Return On Equity -0.4149 City Cranford Uuid c2faef45-30de-37ba-b921-6b91e4daf573
Previous Close 4.15 First Trade Date Epoch Utc 1 B Book Value 0.4740
Beta 1.66 Total Debt 320011 Volume 415694
Price To Book 7.59 Last Split Date 1 B Fifty Two Week Low 2.55
Total Cash Per Share 0.0990 Shares Short Previous Month Date 1 B Target Median Price 54.00
Audit Risk 10 Max Age 86400 Recommendation Mean 2.33
Sand P52 Week Change 0.3133 Target Mean Price 54.00 Net Income To Common -39765352
Short Percent Of Float 0.0796 Implied Shares Outstanding 192 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 17 M Next Fiscal Year End 1 B Held Percent Insiders 0.0681
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 1 Regular Market Previous Close 4.15 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.35 Open 3.60
Free Cashflow -16828150 State NJ Dividend Yield 0.00 %
Return On Assets -0.2474 Time Zone Short Name EST Board Risk 8
Trailing Eps -6.00 Day Low 3.50 Address1 11 Commerce Drive
Shares Outstanding 7 M Compensation Risk 7 Price Hint 4
Target High Price 100.00 Website https://citiuspharma.com 52 Week Change -0.8132
Average Volume 197764 Forward Eps 0.1900 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 431.40 % Last Split Factor 1:25
Regular Market Day High 4.11 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 0.3710 Fifty Two Week High 26.75 Day High 4.11
Shares Short 537856 Regular Market Open 3.60 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0742
Operating Cashflow -29088902 Currency USD Time Zone Full Name America/New_York
Market Cap 27 M Is_nasdaq_100 False Zip 07016
Quote Type EQUITY Industry Biotechnology Long Name Citius Pharmaceuticals, Inc.
Overall Risk 6 Regular Market Day Low 3.50 Held Percent Institutions 0.1322
Current Price 3.60 Address2 First Floor Enterprise To Ebitda -15.43
Financial Currency USD Current Ratio 6.75 Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 158 M
Two Hundred Day Average 15.79 Governance Epoch Date 1 B Enterprise Value 633 M
Forward PE 28.80 Regular Market Volume 415694 Ebitda -41067916
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products.

Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma.

Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed.

The company was founded in 2007 and is headquartered in Cranford, New Jersey.